These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36799235)

  • 21. CIRCULATING CLONAL COMPLEXES AND SEQUENCE TYPES OF STREPTOCOCCUS PNEUMONIAE SEROTYPE 19A WORLDWIDE: THE IMPORTANCE OF MULTIDRUG RESISTANCE: A SYSTEMATIC LITERATURE REVIEW.
    Ruiz García Y; Nieto Guevara J; Izurieta P; Vojtek I; Ortega-Barría E; Guzman-Holst A
    Expert Rev Vaccines; 2021 Jan; 20(1):45-57. PubMed ID: 33507135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study.
    Agudelo CI; Castañeda-Orjuela C; Brandileone MCC; Echániz-Aviles G; Almeida SCG; Carnalla-Barajas MN; Regueira M; Fossati S; Alarcón P; Araya P; Duarte C; Sánchez J; Novas M; Toraño-Peraza G; Rodríguez-Ortega M; Chamorro-Cortesi G; Kawabata A; García-Gabarrot G; Camou T; Spadola E; Payares D; Andrade AL; Di Fabio JL; Castañeda E;
    Lancet Infect Dis; 2021 Mar; 21(3):405-417. PubMed ID: 32986996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase of Macrolide-Resistance in
    Gonzales BE; Mercado EH; Pinedo-Bardales M; Hinostroza N; Campos F; Chaparro E; Del Águila O; Castillo ME; Saenz A; Reyes I; Ochoa TJ
    Front Cell Infect Microbiol; 2022; 12():866186. PubMed ID: 35615398
    [No Abstract]   [Full Text] [Related]  

  • 25. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged <5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine - Kenya, 2009-2010.
    Kobayashi M; Conklin LM; Bigogo G; Jagero G; Hampton L; Fleming-Dutra KE; Junghae M; Carvalho MD; Pimenta F; Beall B; Taylor T; Laserson KF; Vulule J; Van Beneden C; Kim L; Feikin DR; Whitney CG; Breiman RF
    BMC Infect Dis; 2017 Jan; 17(1):25. PubMed ID: 28056828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia.
    Desai AP; Sharma D; Crispell EK; Baughman W; Thomas S; Tunali A; Sherwood L; Zmitrovich A; Jerris R; Satola SW; Beall B; Moore MR; Jain S; Farley MM
    Pediatr Infect Dis J; 2015 Nov; 34(11):1168-74. PubMed ID: 26226445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiological and molecular characterization of Streptococcus pneumoniae carriage strains in pre-school children in Arkhangelsk, northern European Russia, prior to the introduction of conjugate pneumococcal vaccines.
    Vorobieva S Jensen V; Furberg AS; Slotved HC; Bazhukova T; Haldorsen B; Caugant DA; Sundsfjord A; Valentiner-Branth P; Simonsen GS
    BMC Infect Dis; 2020 Apr; 20(1):279. PubMed ID: 32293324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
    Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
    Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
    Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of 13-Valent Pneumococcal Conjugate Vaccine on the Serotype Distribution and Antibiotic Resistance Profiles in Children With Invasive Pneumococcal Disease.
    Gaviria-Agudelo CL; Jordan-Villegas A; Garcia C; McCracken GH
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):253-259. PubMed ID: 26907814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasopharyngeal s. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme.
    Wouters I; Van Heirstraeten L; Desmet S; Blaizot S; Verhaegen J; Goossens H; Van Damme P; Malhotra-Kumar S; Theeten H;
    Vaccine; 2018 Jan; 36(1):15-22. PubMed ID: 29180027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.
    Bruce MG; Singleton R; Bulkow L; Rudolph K; Zulz T; Gounder P; Hurlburt D; Bruden D; Hennessy T
    Vaccine; 2015 Sep; 33(38):4813-9. PubMed ID: 26247901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil.
    Brandileone MC; Almeida SCG; Minamisava R; Andrade AL
    Vaccine; 2018 May; 36(19):2559-2566. PubMed ID: 29650385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.